BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 10469284)

  • 21. Efficacy and safety of zoledronic acid in patients with breast cancer metastatic to bone: a multicenter clinical trial.
    Cartenì G; Bordonaro R; Giotta F; Lorusso V; Scalone S; Vinaccia V; Rondena R; Amadori D
    Oncologist; 2006; 11(7):841-8. PubMed ID: 16880243
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of malignancy-associated hypercalcemia with YM175, a new bisphosphonate: elevated threshold for parathyroid hormone secretion in hypercalcemic patients.
    Fukumoto S; Matsumoto T; Takebe K; Onaya T; Eto S; Nawata H; Ogata E
    J Clin Endocrinol Metab; 1994 Jul; 79(1):165-70. PubMed ID: 8027221
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antiresorptive effect of a single infusion of microgram quantities of zoledronate in Paget's disease of bone.
    Arden-Cordone M; Siris ES; Lyles KW; Knieriem A; Newton RA; Schaffer V; Zelenakas K
    Calcif Tissue Int; 1997 May; 60(5):415-8. PubMed ID: 9115157
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of tumor-induced osteolysis by APD.
    Burckhardt P; Thiébaud D; Perey L; von Fliedner V
    Recent Results Cancer Res; 1989; 116():54-66. PubMed ID: 2762665
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dose/response study of aminohydroxypropylidene bisphosphonate in tumor-associated hypercalcemia.
    Body JJ; Pot M; Borkowski A; Sculier JP; Klastersky J
    Am J Med; 1987 May; 82(5):957-63. PubMed ID: 3578365
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current management strategies for hypercalcemia.
    Pecherstorfer M; Brenner K; Zojer N
    Treat Endocrinol; 2003; 2(4):273-92. PubMed ID: 15966562
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [From laundry product to cancer drug--history of a drug class].
    Possinger K
    Med Klin (Munich); 2000 Oct; 95 Suppl 2():3-7. PubMed ID: 11089381
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages.
    Nussbaum SR; Younger J; Vandepol CJ; Gagel RF; Zubler MA; Chapman R; Henderson IC; Mallette LE
    Am J Med; 1993 Sep; 95(3):297-304. PubMed ID: 8368227
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The incidence of acute anterior uveitis after intravenous zoledronate.
    Patel DV; Horne A; House M; Reid IR; McGhee CN
    Ophthalmology; 2013 Apr; 120(4):773-6. PubMed ID: 23290982
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metastatic bone disease and tumour-induced hypercalcaemia: the role of bisphosphonates.
    Heatley S
    Int J Palliat Nurs; 2001 Jun; 7(6):301-2, 304-7. PubMed ID: 12066026
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Pamidronate in the treatment of tumor-associated hypercalcemia].
    Pecherstorfer M; Janisch S; Marosi C; Wogritsch C; Bosse C; Schratzberger W; Gerber E; Fortelny A; Lenzhofer R; Rainer H
    Klin Wochenschr; 1991 Oct; 69(15):690-5. PubMed ID: 1795492
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy.
    Pecherstorfer M; Herrmann Z; Body JJ; Manegold C; Degardin M; Clemens MR; Thürlimann B; Tubiana-Hulin M; Steinhauer EU; van Eijkeren M; Huss HJ; Thiébaud D
    J Clin Oncol; 1996 Jan; 14(1):268-76. PubMed ID: 8558208
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Decreased efficacy of bisphosphonates for recurrences of tumor-induced hypercalcemia.
    Body JJ; Louviaux I; Dumon JC
    Support Care Cancer; 2000 Sep; 8(5):398-404. PubMed ID: 10975689
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dose-response study of alendronate sodium for the treatment of cancer-associated hypercalcemia.
    Nussbaum SR; Warrell RP; Rude R; Glusman J; Bilezikian JP; Stewart AF; Stepanavage M; Sacco JF; Averbuch SD; Gertz BJ
    J Clin Oncol; 1993 Aug; 11(8):1618-23. PubMed ID: 8336198
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Zoledronate in a patient with pamidronate refractory hypercalcemia syndrome.
    Wenzel C; Bartsch R; Hussian D; Pluschnig U; Locker GJ; Sevelda U; Zielinski CC; Steger GG
    Support Care Cancer; 2004 Sep; 12(9):678-81. PubMed ID: 15160319
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Early, middle, or late administration of zoledronate alleviates spontaneous nociceptive behavior and restores functional outcomes in a mouse model of CFA-induced arthritis.
    Morado-Urbina CE; Alvarado-Vázquez PA; Montiel-Ruiz RM; Acosta-González RI; Castañeda-Corral G; Jiménez-Andrade JM
    Drug Dev Res; 2014 Nov; 75(7):438-48. PubMed ID: 25043808
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Randomized, double-blind, phase II trial of gallium nitrate compared with pamidronate for acute control of cancer-related hypercalcemia.
    Cvitkovic F; Armand JP; Tubiana-Hulin M; Rossi JF; Warrell RP
    Cancer J; 2006; 12(1):47-53. PubMed ID: 16613662
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Malignancy-associated hypercalcemia].
    Oura S
    Nihon Rinsho; 2003 Jun; 61(6):1006-9. PubMed ID: 12806951
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of low level laser therapy and zoledronate on the viability and ALP activity of Saos-2 cells.
    Bayram H; Kenar H; Taşar F; Hasırcı V
    Int J Oral Maxillofac Surg; 2013 Jan; 42(1):140-6. PubMed ID: 22571861
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dose-response in the treatment of hypercalcemia of malignancy by a single infusion of the bisphosphonate AHPrBP.
    Thiébaud D; Jaeger P; Jacquet AF; Burckhardt P
    J Clin Oncol; 1988 May; 6(5):762-8. PubMed ID: 3367184
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.